Clinical impact of 5'MYC or 3'MYC gain/loss detected by FISH in patients with aggressive B-cell lymphomas

被引:3
|
作者
Tang, Guilin [1 ]
Li, Shaoying [1 ]
Toruner, Gokce A. [1 ]
Jain, Preetesh [2 ]
Tang, Zhenya [1 ]
Hu, Shimin [1 ]
Xu, Jie [1 ]
Cheng, Joanne [1 ]
Robinson, Melissa [1 ]
Vega, Francisco [1 ]
Medeiros, L. Jeffrey [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA
关键词
Aggressive B-cell lymphoma; Unbalanced MYC rearrangement; 5 ' MYC gain; deletion; 3 ' MYC gain; DOUBLE-HIT LYMPHOMA; RITUXIMAB-CHOP; DLBCL PATIENTS; MYC; REARRANGEMENTS; CLASSIFICATION; TRANSLOCATIONS; BREAKPOINTS; EXPRESSION; SURVIVAL;
D O I
10.1016/j.cancergen.2022.12.001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
FISH analysis using MYC break-apart probes is a widely used technique to assess for MYC rearrangement (MYC-R). Occasionally, FISH results in atypical signal patterns, such as gain or loss of 5'MYC or 3'MYC. The clinical impact and/or relationship of these atypical signal patterns to MYC-R are unknown. In this study, we assessed 35 patients who had aggressive B-cell lymphomas and exhibited atypical FISH signal pat-terns: 3'MYC deletion ( n = 16) or 3'MYC deletion plus 5'MYC amplification ( n = 5), 5'MYC gain ( n = 10), 5'MYC deletion ( n = 3), and 3'MYC gain ( n = 1). For comparison, we also included 9 patients who showed an unbalanced MYC-R. Patients with 5'MYC gain showed MYC expression and were often refractory to chemotherapy ( n = 7) or had early relapse ( n = 2). By contrast, lymphomas with 3'MYC deletion were negative or had low expression of MYC (16 of 18), and patients often responded to chemotherapy (16 of 19). The median event-free survival was 24, 6, and 4 months for patients with 3'MYC deletion, 5'MYC gain and unbalanced MYC-R, respectively ( p = 0.0048). We conclude that 5'MYC gain is associated with MYC expression and a poorer prognosis and likely represents an unbalanced MYC-R. By contrast, 3'MYC dele-tions are not associated with MYC expression or a poorer prognosis and this finding may be unrelated to MYC-R. (c) 2022 Elsevier Inc. All rights reserved.
引用
收藏
页码:1 / 8
页数:8
相关论文
共 50 条
  • [21] Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification
    Ott, German
    Rosenwald, Andreas
    Campo, Elias
    BLOOD, 2013, 122 (24) : 3884 - 3891
  • [22] Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification
    Ott, German
    Rosenwald, Andreas
    Campo, Elias
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2013, : 575 - 583
  • [23] High level MYC amplification in B-cell lymphomas: is it a marker of aggressive disease?
    Pophali, Priyanka A.
    Marinelli, Lisa M.
    Ketterling, Rhett P.
    Meyer, Reid G.
    McPhail, Ellen D.
    Kurtin, Paul J.
    Mwangi, Raphael
    Maurer, Matthew J.
    Habermann, Thomas
    King, Rebecca L.
    BLOOD CANCER JOURNAL, 2020, 10 (01)
  • [24] MYC-driven aggressive B-cell lymphomas: biology, entity, differential diagnosis and clinical management
    Cai, Qingqing
    Medeiros, L. Jeffrey
    Xu, Xiaolu
    Young, Ken H.
    ONCOTARGET, 2015, 6 (36) : 38591 - 38616
  • [25] MYC Rearranged Aggressive B-Cell Lymphomas: A Report on 100 Patients of the Fondazione Italiana Linfomi (FIL)
    Tisi, Maria Chiara
    Ferrero, Simone
    Dogliotti, Irene
    Tecchio, Cristina
    Carli, Giuseppe
    Novo, Mattia
    Stefani, Piero Maria
    Rattotti, Sara
    Balzarotti, Monica
    Marino, Dario
    Pelosini, Matteo
    Romano, Alessandra
    Flenghi, Leonardo
    Zilioli, Vittorio Ruggero
    Calimeri, Teresa
    Di Napoli, Arianna
    Zanni, Manuela
    Finolezzi, Erica
    Mosna, Federico
    Gini, Guido
    Mansueto, Giovanna
    Di Rocco, Alice
    Tomei, Gabriella
    Sgherza, Nicola
    Olivieri, Jacopo
    Nassi, Luca
    Piazza, Francesco
    Fama, Angelo
    Greco, Antonio
    Giannoccaro, Margherita
    Mazzone, Anna Maria
    Visco, Carlo
    Loseto, Giacomo
    Zaja, Francesco
    HEMASPHERE, 2019, 3 (06):
  • [26] Identifying MYC Rearrangements in Routine Clinical Practice by Screening with MYC Immunohistochemistry: A Single Institution Experience with 272 Consecutive Aggressive B-cell Lymphomas
    Sakr, Hany
    Cook, James R.
    LABORATORY INVESTIGATION, 2017, 97 : 374A - 374A
  • [27] Identifying MYC Rearrangements in Routine Clinical Practice by Screening with MYC Immunohistochemistry: A Single Institution Experience with 272 Consecutive Aggressive B-cell Lymphomas
    Sakr, Hany
    Cook, James R.
    MODERN PATHOLOGY, 2017, 30 : 374A - 374A
  • [28] Utility of LEF1 in Aggressive B-cell Lymphomas with MYC Gene Rearrangement
    Wang, Xin
    Subasi, Nusret
    Faraz, Maria
    Shrestha, Neharika
    Chen, Anne
    Nazeer, Tipu
    Huang, Xiaoyan
    LABORATORY INVESTIGATION, 2024, 104 (03) : S1497 - S1497
  • [29] MYC Signatures and Characterization of MYC-Driven Aggressive B-Cell Lymphoma
    Xu-Monette, Zijun Y.
    Manyam, Ganiraju C.
    Tzankov, Alexander
    Deng, Qipan
    Visco, Carlo
    Tu, Meifeng
    Li, Ling
    Zu, Youli
    Dybkaer, Karen
    Chiu, April
    Orazi, Attilio
    Bhagat, Govind
    Richards, Kristy L.
    Hsi, Eric D.
    Choi, William W. L.
    van Krieken, J. Han
    Huh, Jooryung
    Ponzoni, Maurilio
    Ferreri, Andres J. M.
    Moller, Michael B.
    Farnen, John P.
    Zhao, Xiaoying
    Piris, Miguel A.
    Winter, Jane N.
    Miranda, Roberto N.
    McDonnell, Timothy J.
    Medeiros, L. Jeffrey
    Li, Yong
    Young, Ken H.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 : S223 - S223
  • [30] MYC Gene FISH Testing in Aggressive B-Cell Lymphomas: Atypical Rearrangements May Result in Underreporting of Positive Cases
    Sun, Guoxian
    Montella, Lya
    Yang, Min
    BLOOD, 2012, 120 (21)